Core Insights - AstraZeneca's Imfinzi receives positive recommendation from the European Medicines Agency for bladder cancer treatment [1][2][3] - The recommendation is based on the phase III NIAGARA study, showing a 32% reduction in disease progression risk [3] - Imfinzi is already approved in the U.S. for a similar indication, marking a significant advancement in immunotherapy for muscle-invasive bladder cancer [4] Regulatory Developments - Imfinzi is recommended for use in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer [2] - Regulatory applications for Imfinzi in bladder cancer are under review in Japan and other countries [8] Financial Performance - AstraZeneca's stock has increased by 7.5% year-to-date, contrasting with a 5.7% decline in the industry [5] - Imfinzi generated sales of $1.26 billion in Q1 2025, reflecting a 16% increase driven by demand in lung and liver cancer indications [10] Ongoing Research - Additional studies are underway for Imfinzi targeting other cancer indications, reinforcing its role as a key revenue driver for AstraZeneca's oncology portfolio [10] - The phase III POTOMAC study demonstrated significant improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer patients [9]

Group 1 - The article discusses Wall Street's concerns regarding the implications of Trump's "America First" ideology on the market [1] - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [1] - The company aims to simplify investment strategies, making them accessible to both seasoned and novice investors [1] Group 2 - Allka Research is committed to delivering substantial returns and strategic insights to its clients [1] - The company seeks to empower individuals financially by sharing knowledge and analyses through Seeking Alpha [1] - Allka Research's mission includes fostering a community of informed investors who can navigate the financial markets effectively [1]

AstraZeneca (AZN) stock has declined 6.4% in the past three months.Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market uncertainties and a volatile macroeconomic environment.The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets. Though the massive tariffs imposed by the United States and China are now on a pause, it is only a temporary suspension, and no ...

Investing in growth stocks is a great way to grow your portfolio in the long run. But it can be difficult to predict which ones will take off in value and which one's won't. And that's why it might make sense to invest in multiple growth stocks, to ensure you aren't placing all your hopes on just a single company. Three stocks that possess a lot of long-term potential and are cheap buys right now are Carnival (CCL -2.14%), AstraZeneca (AZN 0.33%), and Block (XYZ -1.70%). At less than $100 per share, here's ...

Astrazeneca (AZN) closed the last trading session at $67.30, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $86.07 indicates a 27.9% upside potential.The mean estimate comprises 10 short-term price targets with a standard deviation of $10.38. While the lowest estimate of $67 indicates a 0.5% decline from the current price level, the most optimistic analyst expects the ...

Tempus AI TodayTEMTempus AI$58.76 +6.57 (+12.59%) 52-Week Range$22.89▼$91.45Price Target$61.08Add to WatchlistTempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance. The company’s results are a testament to its utility, growing at ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank put ...

Company Participants - AstraZeneca's leadership team includes Pascal Soriot as CEO, Aradhana Sarin as CFO, and several executives overseeing various business units and research divisions [1] Conference Call Overview - The Q1 2025 Results Conference Call for AstraZeneca was held to discuss financial performance and operations, welcoming participants from different regions [2] Forward-Looking Statements - The company intends to utilize safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995, indicating that the meeting may contain forward-looking statements regarding operations and financial performance [3] - AstraZeneca acknowledges that forward-looking statements involve risks and uncertainties that could lead to actual results differing from expectations [4]

Astrazeneca (AZN) reported $13.59 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 7.2%. EPS of $1.24 for the same period compares to $1.03 a year ago.The reported revenue represents a surprise of -0.66% over the Zacks Consensus Estimate of $13.68 billion. With the consensus EPS estimate being $1.10, the EPS surprise was +12.73%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

AstraZeneca’s (AZN) first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.10. Core earnings of $2.49 per share rose 21% year over year on a reported basis as well as at constant exchange rates (CER).Total revenues of $13.59 billion rose 7% on a reported basis and 10% at CER, driven by higher product sales and alliance revenues from partnered medicines. However, the metric missed the Zacks Consensus Estimate of $13.68 billion. (Find the latest E ...